Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

This case report highlights that in postmenopausal women with severe hyperandrogenism, thorough adrenal and pelvic evaluations, hormonal profiling, and permanent pathology are essential for accurate diagnosis and management of androgen-secreting tumors, such as AGCTs, to prevent misdiagnosis and ensure effective treatment.

This article discusses topical keratolytic therapy for keratosis pilaris, highlighting potential benefits while noting limitations in the current evidence base, and reports no clinical results.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

The systematic review reported promising outcomes for stem cell-enriched treatments in aesthetic medicine, such as improved skin rejuvenation, hair restoration, and scar revision. However, challenges like protocol variability and regulatory issues must be addressed to ensure effective and safe clinical applications.

This review highlights that alopecia areata is influenced by genetic, autoimmune, and environmental factors, with emerging treatments like JAK-2 inhibitors showing promise for severe cases.

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

The authors updated recommendations on diagnosing and treating women's sexual dysfunctions, emphasizing a comprehensive assessment approach, while noting the need for further multidisciplinary research.

This article discusses the challenges in diagnosing female androgen insufficiency syndrome due to unreliable testosterone measurement methods but notes symptom improvement with testosterone therapy, emphasizing the need for women-specific formulations and safety guidelines.

This article reviews technical aspects of using autologous fat transfer for facial rejuvenation and examines existing evidence for stem cell and platelet-rich plasma therapies in aesthetic practice, reporting no new results.

This review discusses therapies for skin lesions in lupus erythematosus and reports no new clinical results, focusing on defining and managing refractory disease.

This review highlights that platelet-rich plasma and adipose-derived stem cell therapy may offer safe and promising improvements for managing symptoms of genital lichen sclerosus, with a potential synergistic benefit when combined.

This article reviews current and emerging treatments for alopecia areata, emphasizing the need for biomarker-driven patient stratification to optimize therapeutic strategies and reduce potential side effects; it reports no new clinical findings.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This review discusses the clinical implications of female androgen deficiency and evaluates treatment options, emphasizing the need for cautious use of replacement therapy in women with severe deficiency and matching symptoms.

This review discusses the multifactorial causes of female sexual dysfunction and reports no clinical results; it emphasizes the need for thorough evaluation before considering androgen therapy.

This review explores the potential of platelet-rich plasma therapy for early ovarian reserve decline and premature ovarian insufficiency, indicating some ovarian function improvements in initial studies but highlighting the need for further research.

This review discusses biotinidase deficiency, noting that biotin treatment from birth can prevent symptoms, but acknowledges the complexity and need for further understanding due to late-onset cases with varied clinical findings.

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study found that platelet-rich plasma therapy was more effective in increasing hair count than topical 5% minoxidil lotion in men with androgenetic alopecia.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This review discusses the use of platelet-rich plasma in various dermatological applications and reports no new clinical results; the authors call for more rigorous trials to confirm its effectiveness.

This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

This review found that laser-assisted drug delivery in humans was associated with several adverse effects, but no life-threatening events were reported in the studies examined.